Umbilical cord blood (UCB) has emerged as an appealing alternative source of hematopoietic stem cells for unrelated donor transplantation. Shorter time to transplant and an improved chance of finding a suitable graft are evident advantages over bone marrow transplantation from unrelated donors. The majority of UCB transplants from unrelated donors have been performed in children, but the number in adults has been growing steadily in recent years. We review herein the reported experience with that source of hematopoietic stem cells in adults with hematological malignancies. The available data support the use of UCB transplantation from unrelated donors for young adults with hematological malignancies and no appropriate bone marrow donor, especially for those requiring urgent transplantation.
Introduction
During the past three decades, impressive progress has been made in distinct areas of hematopoietic stem cell transplantation (HSCT), allowing the indications for such treatment to be extended to a number of clinical conditions and to diseases previously not regarded as amenable to this radical therapeutic approach. One of the most important advances has been to use alternative donors and sources of transplantable hematopoietic stem cells (HSC) other than bone marrow, such as peripheral blood and umbilical cord blood (UCB).
Both allogeneic bone marrow transplantation and peripheral blood stem cell transplantation from a related human leukocyte antigen (HLA)-identical donor are considered the best options when HSCT is indicated for the treatment of patients with high-risk hematological malignancies, bone marrow failure syndromes, severe congenital immunodeficiency disorders, and some inborn errors of metabolism. However, a suitable related donor is available for only around 30% of potential recipients. To overcome this major limitation, other alternative sources of potentially transplantable HSC have recently been developed. For a further 50-70% of patients with the most common HLA types, a suitably matched unrelated donor is found by searching in the international databases, which contain more than six million potential volunteer donors worldwide. 1 For the remaining patients for whom an HSCT is indicated, but who lack a suitable related or unrelated bone marrow/peripheral blood donor, unrelated donor UCB transplantation (UD-UCBT) has emerged as an appealing alternative. Since 1989, when Gluckman et al 2 reported the first successful UCB transplant from an HLA-identical sibling in a child with severe Fanconi anemia, the number of UCBT from both siblings and unrelated donors has dramatically increased. At present, more than 2000 UCB transplants from unrelated donors have been performed (Table 1 ). The great increase in the use of UD-UCBT has been possible because of the establishment of different cord blood banks worldwide, many of which constitute the Netcord network. The Netcord inventory currently has more than 50 000 cryopreserved UCB units ready for clinical use (Table 1) , and a reasonably accurate worldwide estimate would be 80 000 UCB units. However, the majority of UCB transplants have been performed in children. Current data from Netcord, Eurocord and the New York Blood Center show that the number of UD-UCB transplants in adults represents only a quarter of the total number of UD-UCB transplants. Nonetheless, the number of UD-UCB transplants in adults has been growing steadily in recent years, as shown in Figure 1 (E Gluckman and V Rocha, personal communication). The relatively low frequency of transplants in adults is clearly due to concerns about the risk of graft failure and the delay in hematopoietic recovery. Reasons for this concern include the greater disproportion between the body size of most adult recipients and the number of hematopoietic progenitor cells in a typical UCB unit, which is at least 10 times less than a characteristic bone marrow and almost 100 times less than a peripheral blood stem cell harvest.
In this review, we attempt to integrate all data concerning the experience of UD-UCBT in adults. This is particularly relevant now because some recent reports seem to support the use of UD-UCBT in adults. In fact, the available data suggest that this type of HSCT should be considered a reasonable alternative in young adults with hematological malignancies and no appropriate bone marrow donor, especially in those requiring urgent transplantation. Table 1 The Netcord inventory and use (as of December 2001) Inventory  Transplanted  Children Adults   Barcelona  5036  100  53  47  Denver  6395  109  80  29  Dusseldorf  5789  149  115  34  France Cord  2523  45  37  8  Helsinki  722  0  0  0  Jerusalem  409  19  19  0  Leiden  661  13  11  2  Liege  2032  10  9  1  London  4048  41  31  10  Milan-Grace  6135  172  105  67  New York  11 236  1123  879  244  Sidney  5327  35  23  10  Tokyo  1466  99  58  41   Total  51 779  1915  1420  493 Source: Board of Directors of the International NETCORD Foundation. c/o P Wernet at Institute for Transplantation, Diagnostics and Cell Therapeutics, Heinrich-Heine-University, Germany.
CB Bank

Figure 1
Number of UD-UCBT reported to Eurocord (1994-2000) in children (n = 493) and adults (n = 236). Data were kindly provided by E Gluckman and V Rocha.
Potential advantages and disadvantages of UD-UCBT
In comparison with other sources of allogeneic HSC for transplantation, UCB offers substantial logistic and potential clinical advantages for both the recipient and the donor (Table 2) . Perhaps, the most important advantage is the ready availability of banked cryopreserved UCB units. This superiority translates into a shorter search time and faster transplantation. In a recent study from the University of Minnesota, 3 the median time required to find an unrelated donor was significantly shorter for UCB searches compared with bone marrow searches (14 days vs 49 days, respectively). The median time required to proceed to transplantation in those patients who were actually transplanted was also clearly lower in UCB recipients than in bone marrow recipients (60 days vs 85 days, respectively). The very low risk of transmitting clinically important infections by latent viruses, such as cytomegalovirus (CMV) 4, 5 and Epstein-Barr virus, 6 may also be clinically relevant. Other potential advantages of cord blood derive from the relative immaturity of lymphocytes and the distinctive proliferative advantages of UCB progenitors, including higher cell cycle rates, autocrine production of hematopoietic growth factors, and longer telomeres 7, 8 than are found in bone marrow or peripheral blood HSC. Theoretically, the immaturity of lymphocytes and the lower number of T cells present in UCB units could reduce the risk and severity of graft-versus-host disease (GVHD). This, in turn, may permit a greater degree of HLA discrepancy between donor and recipient than that usually considered acceptable for transplants of blood or bone marrow. As a consequence of accepting a higher degree of HLA mismatch in UCB searches, the odds of finding a suitable donor would improve dramatically. This may represent a major benefit for patients with uncommon tissue types. The almost complete absence of risk to the donor is also relevant. This may be particularly true in those instances where the chance of cure for the recipient is negligible, and the potential risk for an adult unrelated donor is unacceptably high.
However, the potential immunological and proliferative advantages of UCB are counterbalanced by the low number of hematopoietic progenitor cells and HSC in UCB compared with bone marrow or mobilized peripheral blood. In fact, the main potential clinical disadvantage of UCB is related to the lower number of hematopoietic progenitors and stem cells present in a single UCB unit. Furthermore, the immaturity and low number of lymphocytes in cord blood could also be implicated in a higher rate of non-engraftment. Therefore, concern for the increased risk of graft failure and/or delay in hematopoietic engraftment has been, until now, the main reason for the hesitancy in using UD-UCBT, especially in adults. Some preliminary data contributing to this concern 9,10 showed the importance of cell dose for the speed and probability of engraftment after UCBT. However, we now know that this kind of transplantation is capable of promoting sustained hematopoietic engraftment in the great majority of adult recipients. Finally, UCB cells could unwittingly transmit a genetic disorder. Although this risk can be minimized by collecting a meticulous family history and performing laboratory tests for common inherited diseases, it would be almost impossible to remove completely the hazard of transmitting extremely rare genetic diseases.
Leukemia
Clinical experience with UD-UCBT in adults
In the following sections, we will review the reported clinical information regarding the results of UD-UCBT in adults to clarify its real advantages, problems, and possible role in the treatment of severe hematological disorders. At present, only two series of UD-UCBT in adults have been published. 11, 12 In these two reports, 76 patients were transplanted for hematological malignancies and 14 for non-malignant diseases. For the purposes of this review, we have also included available data from two additional series reported in abstract form, one from a single institution 13 and the other from the Eurocord Registry.
14 Anecdotal case reports of UD-UCBT and small series comprising less than 10 patients have not been taken into consideration. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] To comprehend the extraordinary increase in UD-UCBT activity in recent years, we should note that, as of December 1997, a review of reports in the literature 31 collected data from only 43 recipients of UD-UCBT, of whom only four were adults. In fact, the first report of UD-UCBT in an adult patient with chronic myelogenous leukemia was published in 1996. 15 
Patient population
Most characteristics of the recipients in the four series analyzed in this review were remarkably heterogeneous ( Table 3) . The median age of the patients ranged from 26 to 38 years. The median body weight of recipients ranged between 52 and 70 kg, being very similar in two of the series (69 and 70 kg). 11, 12 The slightly lower median weight reported by Eurocord 14 may be related to the inclusion of some patients aged less than 18, while the lower median weight reported by the Japanese investigators 13 might reflect ethnic differences. A similar heterogeneity was observed among the disease-related characteristics of the recipients in terms of both type and status of the disease. The Laughlin series is the only one that included patients without malignancy, while the Sanz series included a larger proportion of patients with chronic myelogenous leukemia. The use of different definitions precludes meaningful comparisons between the series with regard to the status of the disease at transplantation. A previous transplant failed in 10-19% of patients, a figure that seems higher than those reported for unrelated donor bone marrow transplant (UD-BMT). A recent study comparing UD-UCBT and UD-BMT in children with acute leukemia reported a similar finding. 32 The proportion of CMV seropositive patients was higher 
Umbilical cord blood graft characteristics
In contrast to series of UD-BMT, only a small minority of patients undergoing UD-UCBT (nine of 198, 5%) received transplants that were fully matched for all the HLA-A, -B and -DRB1 alleles (Table 4) . The number of patients receiving UCB units that were disparate at one or two HLA loci was 26-59% and 36-54%, respectively. The use of UCB units with a mismatch for three HLA loci was only reported by the Eurocord Registry 14 and in the Laughlin et al 11 series. In the two published papers, the degree of HLA match between the recipient and the graft was determined by serological typing or lowresolution DNA techniques for class I HLA-A and HLA-B alleles, and by high-resolution molecular techniques for class II HLA-DRB1 alleles. 11, 12 In the other two series, this information was not available. In cases where HLA-DRB1 allele typing was performed using low-resolution DNA techniques, the degree of HLA mismatch in these series would have been higher than depicted in Table 4 . As expected, the degree of HLA mismatch increased when class I HLA-A and HLA-B loci were typed by high-resolution DNA techniques. In the series reporting these data, 12 20% of cases showed an additional mismatch with high-resolution typing.
As predicted, the cell dose infused in adult patients was markedly lower than that reported for children. 9, 10 In three of the series, the median number of nucleated cells infused per kilogram of the recipient's body weight ranged very narrowly, from 1.6 × 10 7 /kg to 1.7 × 10 7 /kg. This number was higher in the Japanese series (2.4 × 10 7 /kg), probably due to the lower median body weight of the recipients. Interestingly, several patients received less than 1.5 × 10 7 nucleated cells/kg in all series. Other important data, in view of their potential association with outcome, such as the median number of CD34 + cells 11 and colony-forming unit granulocyte-macrophages (CFU-GM), 33 were only available in two of the reports. 11, 12 Clear differences between these reports were evident, probably reflecting the use of different techniques or problems of reproducibility. We strongly recommend that both the number of CD34 + cells and CFU-GM be reported in future studies. These parameters may well become selection criteria for UCB searches. At present, the content of CD34 + cells and/or CFU-GM in UCB units could be useful in choosing the best graft in those cases where several units are available with similar nucleated cell doses and HLA matches.
Conditioning and GVHD prophylaxis
A variety of conditioning regimens have been used for UD-UCBT. Although most patients were treated with total-body irradiation-based conditioning regimens, there is no evidence that better results were achieved than with chemotherapybased regimens. In the reports of Laughlin et al 11 and Sanz et al, 12 all patients received antithymocyte globulin (ATG) as part of their conditioning, and granulocyte colony-stimulating factor after transplant (Table 5 ). Cyclosporine (CsA), with or without either methylprednisolone or prednisone, was the most frequent prophylaxis for GVHD. Occasionally, other regimens that included methotrexate were also administered. The only study in which patients were homogeneously managed in terms of conditioning and GVHD prophylaxis was that con- 
NA, not available; TBI, total-body irradiation; ATG, antithymocyte globulin; THIO, thiotepa; BU, busulfan; CY, cyclophosphamide; FLU, fludarabine; G-CSF, granulocyte colony-stimulating factor; GVHD, graft-versus-host disease; CsA, cyclosporine; PRED, prednisone, prednisolone or methylprednisolone; MTX, methotrexate.
Leukemia ducted by the University Hospital La Fe. 12 Patients at this center were conditioned with thiotepa, busulfan, cyclophosphamide and ATG, and CsA and prednisone were given for GVHD prophylaxis.
Hematological recovery
The myeloid engraftment rate at 60 days was 81-100% (Table  6 ). The median time to achieve an absolute neutrophil count (ANC) above 0.5 × 10 9 /l ranged considerably, from 22 days in the Spanish 12 and Japanese series 13 to 32 days in the series by Eurocord.
14 In large UD-UCBT series involving mainly children, the principal factors affecting the rate and/or speed of myeloid engraftment were the cell dose of UCB units in terms of the number of nucleated cells and CFU-GM per kilogram of the recipient's body weight, the type of disease, the extent of HLA disparity, and a center effect. 9, 10, 33 At present, the only characteristic that has shown a relationship with the time to myeloid engraftment in adults undergoing UD-UCBT has been the number of nucleated cells in the UCB before freezing. 11 As previously shown, the nucleated cell dose in the different series of UD-UCBT in adults did not differ markedly, with the Table 6 Unrelated donor cord blood transplantation in adults: engraftment, GVHD and outcome /l. NA, not available; ANC, absolute neutrophil count; GVHD, graft-versus-host disease; TRM, transplant-related mortality; EFS, event-free survival.
exception of the Japanese series. 13 Therefore, this factor by itself does not explain the differences among the series regarding the speed of myeloid engraftment. Other characteristics of the graft and/or the patient, at present unknown, must be involved. We speculate that the quick engraftment reported by the Spanish group, faster than that observed in children receiving grafts with a much higher nucleated cell dose, 9, 10 could be related in part to the conditioning regimen. 12 The addition of thiotepa and ATG to the classic busulfan-cyclophosphamide regimen could have eased the engraftment. In fact, the administration of thiotepa and ATG has been demonstrated to dramatically reduce the rate of immune rejection in T cell-depleted transplants from HLA-identical siblings and from haploidentical relatives. 34, 35 Recent data in children with hemoglobinopathy undergoing UCBT from a related donor have also suggested that an intensified conditioning regimen was associated with quicker myeloid engraftment. 36 Platelet engraftment was generally delayed after UD-UCBT (Table 6 ). In two of the four series of UD-UCBT in adults, 11, 12 the median time to achieve a platelet count above 20 × 10 9 /l was similar to that reported in large series of UD-UCBT in children. 9, 10 However, this time was significantly longer in the Eurocord series, 14 whereas it was clearly shorter in the Japanese one (38 days to a platelet count above 50 × 10 9 /l). 13 The reasons for these differences are unclear. The cumulative probability of platelet engraftment at 180 days was 65-90%. Furthermore, in the Spanish series, 12 all cases with sufficient follow-up demonstrated a complete and sustained recovery of platelet counts to normal levels. In that report, full donor chimerism was observed in all engrafted patients. 12 All these data suggest that, as in children, 32,37 the probability of engraftment in adults undergoing UD-UCBT is similar to that observed after HLA-matched UD-BMT. 38 To our knowledge, no late graft failures have been reported.
GVHD
Data from registries 9,10 that mainly include children, and from two recent non-randomized comparative studies of UD-UCBT and UD-BMT in children, 32, 37 suggest that the risk of acute and chronic GVHD after UD-UCBT is similar or even lower than after unmanipulated UD-BMT, despite a higher degree of HLA mismatch. Preliminary data suggest than the same is true in adults ( Table 6 ). The probability of developing grade II to IV acute GVHD and extensive chronic GVHD ranged from 30 to 63% and from 3 to 50%, respectively. As well as small sample size, subjective application of the grading system for reporting GVHD among marrow transplant centers may account for these differences, at least in part. Obviously, unrecognized factors could also be involved in the variable incidence of GVHD reported. It has been speculated that the clinical pattern of chronic GVHD after UD-UCBT could be somewhat different to that usually seen after UD-BMT. 28 
Transplant-related mortality
A high TRM is the major drawback of UD-UCBT. This may be due to slower hematopoietic recovery, GVHD, regimenrelated toxicity, or impaired immunological reconstitution. Early TRM in adult series ranged from 9 to 12%, with an astounding increase at day 100 (range, 43-54%). It is likely that increasing experience with UD-UCBT, including better selection of the UCB unit, may reduce TRM, as occurred in the UD-BMT context. 39, 40 In fact, the preliminary data for UD-UCBT in adults reported by Eurocord show a significant reduction in TRM at day 100 for those transplants performed after January 1998. 14 
Long-term outcome
At present, the long-term outcome, in terms of overall survival and event-free survival (EFS), of UD-UCBT in adults cannot be properly evaluated because of small sample sizes, short follow-up, and heterogeneous patient populations. Initial concern about an increased risk of relapse after UD-UCBT, compared with UD-BMT, has not been substantiated by recent data in children. 32, 37 The lack of information on adults pre-cludes a meaningful analysis of this issue. In the reviewed series, EFS ranged from 21% at 1 year to 76% at 36 months (Table 6) , probably reflecting differences in the study population.
Factors influencing outcome
The cell dose infused, measured as total nucleated cells per kilogram of the recipient's body weight 9, 10 and CFU-GM per kilogram of the recipient's body weight, 33 the status of the disease at transplant, 41 the degree of HLA match, 42 and the age of the recipient 42 have emerged as strong indicators of survival after UD-UCBT in studies involving mainly children. In adults undergoing UD-UCBT, information on prognostic factors influencing short-term engraftment and long-term outcome is still very limited. In a joint study by five US institutions, 11 the presence of a high number of CD34 + cells in the graft was associated with improved EFS. In the Spanish series, 12 age at transplantation had a clear impact on EFS, with a poorer outcome for patients over 30 years of age. The most relevant factors for survival in the Eurocord series were the status of the disease at transplantation and the nucleated cell dose infused.
14 Interestingly, in that study, the unfavorable effects of a low nucleated-cell dose infused was particularly evident for patients receiving a very low cell dose (less than 1 × 10 7 nucleated cells per kilogram). Patients with standard risk disease status at UCBT also showed a trend for better survival in the Spanish and Japanese series. 12, 13 The degree of HLA disparity did not seem to influence outcomes in any of the studies.
UD-UCBT in adults vs other alternative donor transplants
No study comparing UD-UCBT in adults to matched UD-BMT or transplants with highly HLA-disparate haploidentical family donors has been made to date. As mentioned before, two pediatric studies have shown no difference in survival between patients receiving UD-UCBT and UD-BMT. 32, 37 No comparison has been made in children between UD-UCBT and transplantation from disparate haploidentical family donors. A recent study of adults 43 has shown superior survival in matched UD-BMT recipients compared with BMT from disparate haploidentical family donors. The role of UCB in the alternative donor algorithm for adults has yet to be defined by performing comparative studies of all these forms of HSCT.
Summary and future perspectives
UD-UCBT can restore hematopoiesis in adults who receive myeloablative therapy and is associated with acceptable rates of acute and chronic GVHD despite HLA mismatching. At present, long-term outcomes cannot be properly assessed due to low numbers, heterogeneity of patient populations, and lack of long-term follow-up.
The major aim of future research into UD-UCBT should focus on reducing TRM. To achieve this goal several approaches are being explored. Encouraging results concerning engraftment and TRM have recently been reported with the use of reduced-intensity conditioning regimens. 26, 30, 44, 45 Another potential approach to reduce TRM in UD-UCBT is to reduce the time of engraftment by using ex vivo expanded cord blood units. 24, 46, 47, 48 However, some concerns have Leukemia been expressed because of the possible negative impact of these methods on long-term engraftment. 49, 50 The combination of expanded and unmanipulated fractions of UCB graft could provide rapid short-and long-term engraftment. 47 The cotransplantation of UCB units, either with additional UCB units 51, 52 or with highly purified CD34 + cells from haploidentical family donors, 30 is currently under evaluation as an alternative technique with which to reduce the time to neutrophil recovery.
In summary, UCB has emerged as an appealing alternative source of hematopoietic stem cells for unrelated donor transplantation. Shorter time to transplant and an improved chance of finding a suitable graft are evident advantages of UD-UCBT over UD-BMT. Although many questions remain unanswered, all available data suggest that UD-UCBT should be considered an acceptable option in cases of adult patients with hematological malignancies or severe bone marrow failure for whom an HLA-matched unrelated donor is not readily available. This is particularly relevant to patients requiring urgent transplantation. A prospective randomized study comparing UD-UCBT to UD-BMT is clearly required. This will allow us to determine the role of UD-UCBT in the alternative donor algorithm for adults with hematological malignancies.
